{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"14.000","floor":"12.500"},"ipodate":{"start":"2018-10-18 00:00:00","end":"2018-10-23 00:00:00"},"minimumcapital":"7070.54","subscribed":"1.11","marketcap":"156.32億","H_marketcap":"--","pe":"--","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/01801/LTN20181018028_C.pdf","ipopricing":"13.980","resultdate":"2018-10-30 00:00:00","enddate":"2018-10-23 00:00:00","listeddate":"2018-10-31 00:00:00","issuenumber":"23635.00萬","issuenumberhK":"2363.50萬","issuenumberother":"21271.50萬","grayprice":"14.10","sponsors":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,摩根大通證券(遠東)有限公司,招商證券(香港)有限公司","raisemoney":"315530.00萬","use":"1、52%或約1640.8百萬港元用于撥資正在進行及計劃中的信迪利單抗(IBI-308)臨床試驗、注冊備案的準備事宜及計劃的商業化推出（包括銷售及市場推廣）\n2、8%或約252.4百萬港元用于撥資正在進行及計劃中的IBI-305臨床試驗、注冊備案的準備事宜及計劃的商業化推出（包括銷售及市場推廣）；\n3、4%或約126.2百萬港元用于撥資正在進行及計劃中的IBI-301臨床試驗、注冊備案的準備事宜及計劃的商業化推出（包括銷售及市場推廣）；\n4、1%或約31.6百萬港元用于撥資正在進行及計劃中的IBI-303臨床試驗、注冊備案的準備事宜及計劃的商業化推出（包括銷售及市場推廣）。\n5、25%或約788.8百萬港元用于撥資正在進行及計劃中的其他管線候選藥物的臨床試驗、注冊備案的準備事宜及潛在的商業化推出（包括銷售及市場推廣）。\n6、10%或約315.5百萬港元，用作營運資金及一般公司用途。","shares":500,"leadagent":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,摩根大通證券(亞太)有限公司,招商證券(香港)有限公司,華泰金融控股(香港)有限公司,香港上海匯豐銀行有限公司","bookrunners":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,摩根大通證券(亞太)有限公司,招商證券(香港)有限公司,華泰金融控股(香港)有限公司,香港上海匯豐銀行有限公司","coordinator":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,摩根大通證券(亞太)有限公司,招商證券(香港)有限公司,華泰金融控股(香港)有限公司","firstDayOpen":"14.30","IsEiio":0,"Interestdays":7,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E01801","name":"信達生物－Ｂ","fullname":"信達生物制藥"},"institutioninfo":{"principaloffice":"中國蘇州工業園區東平街168號","registrars":"香港中央證券登記有限公司","registrarstel":"(852)2862 8628","chairman":"俞德超","secretary":"王艷菊,陳濼而","telephone":"(86512)6956 6088","substantialshareholders":"Great Biono Fortune LP(8.06%),其他首次公開發售前投資者(47.73%),境內首次公開發售前投資者(16.72%)","principalactivities":"公司的使命是創立一家世界級的中國生物制藥公司，開發并銷售老百姓能買得起的優質藥物。","website":"www.innoventbio.com"},"managerinfo":[{"managername":"俞德超","post":"主席、總裁、首席執行官兼執行董事","rankno":1},{"managername":"奚浩","post":"首席財務官兼執行董事","rankno":2},{"managername":"陳樹云","post":"非執行董事","rankno":3}],"investorinfo":[{"institutionname":"SCC Growth V Holdco L, Ltd.","shareholding":"33,640,000.0","percentage":14.2,"ReleaseDate":"2019-04-30 00:00:00","relatedparty":"Sequoia Capital China Growth Fund V, L.P.","subsidiary":["SCC Growth V Holdco L, Ltd."],"InverstorType":"公司"},{"institutionname":"惠理基金管理香港有限公司","shareholding":"16,820,000.0","percentage":7.1,"ReleaseDate":"2019-04-30 00:00:00","relatedparty":"惠理集團有限公司","subsidiary":["惠理基金管理香港有限公司"],"InverstorType":"公司"},{"institutionname":"Prime Capital Funds","shareholding":"16,819,000.0","percentage":7.1,"ReleaseDate":"2019-04-30 00:00:00","relatedparty":"涌金資產管理有限公司","subsidiary":["Prime Capital Funds","Dragon Billion China Master Fund"],"InverstorType":"基金"},{"institutionname":"Cormorant Asset Management, LP","shareholding":"14,016,500.0","percentage":5.9,"ReleaseDate":"2019-04-30 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"}],"TotalShareholdingPercentage":58.1},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":510}